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a b s t r a c t
Spinocerebellar ataxia 15 (SCA15) is a clinically heterogeneous movement disorder charac-
terized by the adult onset of slowly progressive cerebellar ataxia. ITPR1 is the SCA15
causative gene. However, despite numerous reports of genetically-conﬁrmed SCA15, phe-
notypic uncertainty persists. We reviewed the phenotypes of 60 patients for whom SCA15
was conﬁrmed by the presence of a genetic deletion involving ITPR1. The most prevalent
symptoms were gait ataxia (88.3%), dysarthria (75.0%), nystagmus (73.3%), and limb ataxia
(71.7%). We also present a novel SCA15 phenotype in a woman with an ITPR1 variant found to
have hydrocephalus that improved with ventriculoperitoneal shunting. This is the ﬁrst
reported case of hydrocephalus associated with SCA15. In this review, we analyzed previ-
ously reported SCA15 phenotypes and present a novel SCA15 phenotype. We also address
important considerations for evaluating patients with complex hereditary movement dis-
orders.
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Spinocerebellar ataxias (SCAs) are a group of complex
hereditary movement disorders that are challenging to
diagnose due to their clinical heterogeneity. Harding [1]
stratiﬁed those with autosomal-dominant inheritance into
three categories of autosomal dominant cerebellar ataxia
(ADCA) based upon clinical presentation. Genetic analyses* Corresponding author at: Department of Neurology, Mayo Clinic, 450
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0028-3843/# 2016 Published by Elsevier Sp. z o.o. on behalf of Polish have led to improved disease classiﬁcations, which have
enabled the association of SCA with speciﬁc genetic distur-
bances.
SCA15 was ﬁrst described by Storey et al. [2] in an Australian
family with ‘‘pure’’ cerebellar ataxia. There have been several
reports of patients with SCA15, and each has been phenotypi-
cally different. However, the genetic speciﬁcity of this disease
increases as the efﬁciency of genetic analyses improves.
Genetic analysis of the original Australian family (AUS1)0 San Pablo Road, 32224 Jacksonville, FL, United States.
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Fig. 1 – Pedigree structure of the proband's family. Standard
symbols were used. Round symbols indicate females,
squares indicate males, and diagonal lines indicate that
the individual is deceased. Diamonds were used to
disguise sex, and numbers inside symbols indicate
number of children. The arrow indicates the proband. Black
symbols indicate individuals with clinical features of
ataxia.
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(inositol triphosphate receptor 1) gene [3]. This was further
speciﬁed within the same family by van de Leemput et al., who
described a deletion involving exons 1–10 of ITPR1 and half of
the neighboring SUMF1 (sulfatase modifying factor 1) gene [4].
Despite thorough reporting of SCA15 phenotypes [2,5–13],
there is no consensus on a speciﬁc constellation of SCA15
symptoms. Therefore, diagnosis is made by genetic analysis.
The purpose of this review is to list previously reported
SCA15 phenotypes matched with the their most current
genetic analyses, present a novel SCA15 phenotype, and
propose a diagnostic approach to this disorder.
2. Characterizing SCA15
SCA15 is deﬁned by a speciﬁc genetic locus. Since the locus was
identiﬁed, clinicians have tried to deﬁne the SCA15 phenotype
so that it may be clinically differentiable from other diseases.
2.1. The SCA15 locus and SCA16
In 2007, van de Leemput described three SCA15 families,
including the original AUS1 family, whose genotyping revealed
deletions involving the ITPR1 and SUMF1 genes [4]. Synofzik
et al. reported ﬁve SCA15 families, and four had deletions
involving both genes, but one family's deletion included only
ITPR1 [9]. Since that time, all reported SCA15 families have had
deletions involving ITPR1 thus establishing it as the causative
gene of SCA15.
SCA16 was ﬁrst described in 2001 by Miyoshi et al. in a
Japanese family with nine affected individuals, and all had
nystagmus and truncal ataxia [5]. Magnetic resonance imaging
(MRI) of the affected individuals showed cerebellar atrophy
without brainstem involvement, and genetic analysis sug-
gested linkage to a locus on chromosome 8q22.1-24.1. The
locus was later reassigned to 3p26.2-pter, and a point mutation
was identiﬁed within the contactin 4 gene (CNTN4) [14]. This
region overlapped with the SCA15 3p24.2-3pter locus identiﬁed
three years earlier [3]. Further analysis of this family by Iwaki
et al. yielded a heterozygous deletion limited to exons 1–48 of
ITPR1, indicating that haploinsufﬁciency of ITPR1 was the
cause of both SCA15 and SCA16 [15]. Gardner proposed
designating SCA16 a ‘‘vacant SCA’’ and that any adult onset
ITPR1-associated cerebellar ataxia should be referred to as
SCA15; however, the nomenclature of SCA15/16 continues to
be used [16]. This is important because the SCA15 phenotype is
not clearly deﬁned. Excluding phenotypes from SCA15 by
mislabeling them as SCA16 artiﬁcially limits the phenotypic
spectrum of disease.
2.2. Phenotypes
Since the ﬁrst report by Storey et al. [2], several phenotypic
descriptions have been documented. A recent systematic
review of ADCAs showed that when compared to other SCAs,
there was a signiﬁcantly higher proportion of SCA15/16
patients with intention/postural tremor at disease onset. This
review showed that throughout the disease course, higher
proportions of SCA15/16 patients had nystagmus, but visualimpairment was not as common in these patients [17]. We
present the most current compilation of SCA15 phenotypes in
Table 1, which contains only publications with detailed
phenotypic descriptions. We also noted the most speciﬁc
genetic deletion information, which in some cases, was
obtained from subsequent publications. A complete list of
reported SCA15 phenotypes matched to speciﬁc genetic
alterations has never been published. Within these reports,
we found sixty individuals whose phenotypes were described
in detail. There is considerable variability among the pheno-
typic descriptions; however, the high prevalence of some traits
helped deﬁne the SCA15 phenotype. At least three-fourths of
the individuals had gait ataxia and dysarthria, while more
than half exhibited limb ataxia and nystagmus. Other features
frequently seen included tremor, pyramidal signs, and truncal
ataxia. Table 2 shows percentages of patients exhibiting each
clinical feature. Because pertinent negatives are not regularly
reported, phenotype prevalence data is based on the assump-
tion that if an exam ﬁnding was not reported then it was
absent.
3. Novel case of SCA15
The proband, a 59-year-old woman, presented with chronic,
progressive gait ataxia. Physical examination revealed lower
extremity spasticity with mild hyperreﬂexia, bilateral ankle
clonus, and positive Babinski's sign bilaterally. She had
reduced touch, pinprick, temperature, and vibration sensa-
tions in a distance-dependent manner up to the elbows and
knees bilaterally. Her gait was spastic, and she had a resting
tremor in her right hand. The patient's father had dementia, a
shufﬂing gait, and normal-pressure hydrocephalus. The
pedigree structure is presented in Fig. 1. MRI of the brain
showed severe enlargement of the lateral and third ventricles,
which was compatible with hydrocephalus that was likely
secondary to aqueductal stenosis (Fig. 2).
3.1. Genetic evaluation
Whole-exome sequencing (WES) was performed using a blood
sample from the proband and saliva samples from both of her
Table 1 – SCA15 and SCA16 study summaries.
Study SCA
subtype
Phenotype description Neuroimaging Ethnicity Genetics
Storey et al., 2001 [2],
van de Leemput
et al., 2007 [4]
SCA15 Limb ataxia, gait ataxia,
titubation, dysphagia, dysarthria,
dysmetric saccades, VOR gain <1,
failure to suppress VOR,
pyramidal signs, tremor
Cerebellar vermal
hypoplasia
Australian
(AUS1)
Deletion of ITPR1 exons 1–10
& SUMF1 exons 1–3
Miyoshi et al., 2001 [5],
Miura et al., 2006 [14]
SCA16 Gait ataxia, limb/truncal ataxia,
nystagmus, titubation,
dysarthria
Cerebellar atrophy
particularly at the
vermis
Japanese Deletion of 3p26.2-pter and
one point mutation (4256C:
T) in the 30 untranslated
region of (CNTN4) on 3p26.2-
26.3.
Hara et al., 2004 [6],
Hara et al., 2008 [18]
SCA15 Limb/truncal ataxia, nystagmus,
pyramidal signs, hyporeﬂexia,
tremor
– Japanese 414 kb deletion including
entire ITPR1 and exon 1 of
SUMF1. C->T substitution at
position 8581 of ITPR1
van de Leemput
et al., 2007 [4]
SCA15 Cerebellar ataxia – English 1. Deletion of ITPR1 exons 1–
40 & SUMF1 exons 1–3
2. Deletion of ITPR1 exons 1–
44 & SUMF1 exons 1–3
Iwaki et al., 2008 [15] SCA16 – – Japanese Deletion of ITPR1 exons 1–48
Ganesamoorthy
et al., 2009 [19]
SCA15 Cerebellar ataxia – Australian ITPR1 exons 1–38 & SUMF1
intron 1
Novak et al., 2010 [7] SCA15/16 Truncal ataxia, gait ataxia,
dysdiadochokinesia, nystamgus,
impaired smooth pursuit,
dysarthria, dysmetric saccades,
pyramidal signs, tremor
Predominantly
vermal cerebellar
atrophy with mild
parietal/temporal
volume loss
English 346,487 bp deletion
including SUMF1 exons 1–3
& ITPR1 exons 1–48
Di Gregorio
et al., 2010 [8]
SCA15 Limb/truncal ataxia, gait ataxia,
nystagmus, dysphagia,
dysarthria, pyramidal signs,
buccolingual dyskinesia, facial
myokymia, hypopallesthesia,
cognitive/psychiatric symptoms,
tremor
Predominantly
vermal cerebellar
atrophy
Italian 1. Deletion of ITPR1 exons 1–
39
2. Deletion of SUMF1 exon 7
– ITPR1 exon 59
Synofzik
et al., 2011 [9]
SCA15 Gait ataxia, nystagmus,
dysphagia, dysarthria, dysmetric
saccades, pyramidal signs,
hyporeﬂexia, upward gaze palsy,
cognitive/psychiatric symptoms,
tremor, abnormally evoked
motor & somatosensory
potentials, dysmetria
Vermal cerebellar
atrophy
German 1. Heterozygous deletion of
entire ITPR1.
2. Partial deletion of both
ITPR1 and SUMF1
Marelli et al., 2011 [10] SCA15 Limb ataxia, gait ataxia,
nystagmus, impaired smooth
pursuit, dysphagia, dysarthria,
pyramidal signs, tremor
Global or
predominantly
vermal cerebellar
atrophy
Mostly
Western
European
1. Deletions involving only
ITPR1
2. Deletions involving ITPR1
and SUMF1
3. Deletion involving ITPR1,
SETMAR, and SUMF1
Castrioto et al., 2011 [11] SCA15 Gait ataxia, impaired smooth
pursuit, titubation, dysphagia,
dysarthria, hypophonia,
pyramidal signs, hypotonia,
cognitive/psychiatric symptoms,
dysmetria, chorea
Cerebellar atrophy
with verbal
involvement
Italian Deletion of SUMF1 exon 5
through ITPR1 (ITPR1 exons
34–52 & SUMF1 exons 6–8
were not tested)
Obayashi
et al., 2012 [12]
SCA15 Gait ataxia, pyramidal signs,
cognitive/psychiatric symptoms,
tremor
– Japanese ITPR1 deletion preserving
exon 48 & 59 and SUMF1
exon 1 & 2
Orsucci
et al., 2013 [13]
SCA15 Gait ataxia, myoclonic jerks,
hyporeﬂexia
Atrophy of dorsal
cerebellar vermis
– Deletions in exons 3 & 4 of
ITPR1
Abbreviations: VOR, vestibuloocular reﬂex; SUMF1, sulfatase-modifying factor 1; CNTN4, contactin 4, ‘‘-’’ indicates that the study did not report
this information.
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Fig. 2 – Magnetic resonance images of the proband. (A) Sagittal T1-weighted, and (B) axial T2 weighted images with fat
saturation showing ventriculomegaly (white arrow) and aqueductal stenosis (white arrow heads). L = left side.
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purposes only, and no approval from the local institutional
review board was sought or required. Exome sequencing of a
family trio resulted in an average of 11–15 giga base pairs of
sequence per sample, and approximately 90% of the bases
were expected to have a quality score of Q20 or higher.
A variant designated as c.4402G>A (p.Val1468Ile) was
detected in exon 34 of ITPR1. Capillary electrophoresis
conﬁrmed the presence of this variant in the proband. Next-
generation sequencing revealed the same variant in the
proband's father. This missense variant has been reported
in 3 European-American individuals in the NHLBI ESP
database, which indicates that there is an allele frequency
of 0.00036337209. It has also been reported in 15 of 66,732Table 2 – SCA15 phenotype characteristics.
Symptom Patients affected, n (%)
Gait ataxia 53 (88.3)
Dysarthria 45 (75)
Nystagmus 44 (73.3)
Limb ataxia 43 (71.7)
Tremor 28 (46.7)
Truncal ataxia 25 (41.7)
Pyramidal signs 24 (40)
Dysphagia 15 (25)
Dysmetric saccades 15 (25)
Impaired smooth pursuit 13 (21.7)
Dysmetria 10 (16.7)
Cog/Psych 7 (11.7)
Abbreviation: Cog/Psych: cognitive/psychiatric test.European alleles in the ExAC dataset, indicating an allele
frequency of 0.0002248. It has not been reported in the 1000
Genomes population. In silico models were discordant with
regard to prediction of pathogenicity, and the variant was
classiﬁed as a variant of uncertain signiﬁcance.
3.2. Treatment
Prior to a therapeutic lumbar puncture, the patient had
reduced arm swing bilaterally and multiphase turning but
was able to recover on the pull test (Supplemental video 1). The
opening pressure was 128 mm of water. The patient's gait
signiﬁcantly improved following the lumbar puncture, and she
underwent placement of a ventriculoperitoneal shunt. The
improvement has persisted through our most recent follow up
(Supplemental video 2).
There are no previous reports of SCA15-associated hydro-
cephalus. Moreover, there is no known link between the SCA15
locus and aqueductal stenosis or hydrocephalus. This case
adds to the diverse phenotype of SCA15 and illustrates the
importance of thorough genetic investigation.
4. Practical application and clinical
considerations
Because of the signiﬁcant phenotypic variation, the diagnosis
of SCA15 requires more than clinical symptomatology. Based
upon our analysis of previously reported SCA15 phenotypes,
we propose that SCA15 should be considered in cases of adult-
onset, chronic, progressive ataxia with dysarthria and
evidence suggesting an autosomal-dominant inheritance
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for SCA15 include limb ataxia and nystagmus, but other
ﬁndings including tremor, pyramidal signs, and truncal ataxia
may also be present. Compared to other SCAs, SCA15 has a
signiﬁcantly higher proportion of intention/postural tremor
and nystagmus, while visual impairments, neuromuscular
disorder, and autonomic dysfunction are present in fewer
patients [17]. The next stage in diagnosis should include
testing to rule out the most common nongenetic etiologies.
Our case suggests that even when signiﬁcant ﬁndings such as
hydrocephalus are identiﬁed; it is prudent to conduct a genetic
evaluation if supported by a strong family history. While
trinucleotide-repeat disease represents the majority of SCAs,
SCA15 was reported as the most common nontrinucleotide-
repeat SCA in Central Europe representing 8.9% of the
remaining SCAs [9]. Therefore, one should rule out trinucleo-
tide repeat expansions with commercially-available genetic
testing prior to moving on to other genetic studies, such as
WES.
Genetic testing may uncover a novel variant, but there may
not be sufﬁcient evidence to prove pathogenicity. These
variants of uncertain signiﬁcance should not be interpreted
as clinically insigniﬁcant. Our patient's variant is located
within the causative gene for SCA15. This was clinically
signiﬁcant because SCA was in the differential diagnosis of her
condition. An advantage of genetic testing is that as data
accumulates in genetic databases, variants previously desig-
nated as having uncertain signiﬁcance can be reanalyzed in a
stronger database and have a better chance of signiﬁcance.
Moreover, the quality of genetic testing is rapidly improving.
This concept of improved genetic analysis is illustrated in
Table 1 by the genotype found by Hara and colleagues in their
Japanese family. In 2004, they reported a deletion of 3p26.1-
25.3, and four years later were able to further specify a 414-kb
deletion, including entire ITPR1 and exon 1 of SUMF1 [6,18].
Another question of many practicing neurologists is
whether testing patients for diseases that have no cure or
treatment is valuable. In the age of exponentially rising
healthcare costs, this point is well taken; however, some
important considerations should be made when choosing to
have a patient genetically tested. We propose that genetic
testing would actually save money by ending the patient's
diagnostic odyssey. Further diagnostics such as expensive
imaging studies would not be needed if genetic testing reveals
disease. Additionally, in diseases where effective treatments
are lacking, the ability to identify a disease would provide
prognostic information and help patients make informed
decisions regarding reproductive planning. Disease identiﬁca-
tion also helps patients take action. Knowing what disease a
patient has may allow him or her to join appropriate support
organizations and establish their candidacy for research
studies. This can be empowering and therapeutic for patients
with currently incurable diseases.
5. Conclusions
SCA15 is an autosomal dominant movement disorder charac-
terized by slowly progressive cerebellar ataxia. Like many
other clinically heterogenous movement disorders, SCA15presents a signiﬁcant diagnostic challenge to clinicians. We
reviewed the literature and summarized the phenotypic
ﬁndings of 60 individuals with ITPR1-related ataxia. Among
the reported cases, the most common ﬁndings were gait
ataxia, dysarthria, nystagmus, and limb ataxia. We also
presented the case of a patient with a novel presentation of
treatable SCA15-associated hydrocephalus. When SCA is
suspected, genetic testing should be performed. Whole-exome
sequencing is a cost-effective tool that should be in the
practicing neurologist's armamentarium of diagnostic tests.
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